Table 1.

Model Recommended Treatment Strategies Required to Achieve EPHP in Low- to High-Prevalence Settings for Schistosoma mansoni and S. haematobium

Prevalence in SAC Prior to Treatment	Model Recommended Treatment Strategy
Low (<10%)	S. mansoni: 75% SAC annual treatment for 0–1 y (no treatment needed where EPHP met prior to treatment).
Moderate (10%–50%)	S. mansoni: 75% SAC annual treatment for 1–3 y (1–2 y for low adult burden of infection and 3 y for high adult burden of infection). S. haematobium: 75% SAC annual treatment for 0–1 y (no treatment needed where EPHP met prior to treatment).
High (≥50%)	S. mansoni and S. haematobium (where baseline SAC prevalence is 50%–51%): 75% SAC annual treatment for up to 1–4 y (1 y for S. haematobium; 2 y for low adult burden of infection, and 4 y for high adult burden of infection for S. mansoni).
	S. mansoni (where baseline SAC prevalence is below 73% and 59%, for low and high adult burdens of infection, respectively) and S. haematobium (where baseline SAC prevalence is below 70%): 75% SAC annual treatment for 7 y.
	S. mansoni and S. haematobium (with baseline SAC prevalences higher than those above): Increase in school-based treatment coverage (ie, over 75% SAC annual treatment for 7 y) and/or expansion to community-wide treatment needed. Coverage levels increase with the adult burden of infection.

Age-intensity profiles shown in Figure 1A were used.

Recommendations are for a single community (set at 500 individuals in the model). Corresponding parameter values, including prevalence threshold values for the age-intensity profiles investigated, are shown in Supplementary Tables 1–5.

Abbreviations: EPHP, elimination as a public health problem; SAC, school-aged children 5–14 years old; y, year(s).